
Home » ANTIDEPRESSANT LU AA21004 MOVED INTO PHASE II TRIALS
ANTIDEPRESSANT LU AA21004 MOVED INTO PHASE II TRIALS
Lundbeck has announced plans to to investigate Lu AA21004 for the treatment of depression in patients and will enrol the first patient in a 400 patient Phase II study by the end of third quarter 2006. The decision is based on positive pre-clinical results as well as positive
conclusion of the Phase I trials in healthy individuals.
Lu AA21004 is
the most advanced project in Lundbeck within a new chemical class, the bis-aryl-sulphanyl
amines. The pharmacology of these projects is markedly different from any currently
marketed antidepressants.
Compared with currently approved antidepressants
preclinical models have demonstrated Lu AA21004 to address important unmet needs
for patients on both fast onset of effect and increased efficacy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
30Nov
-
05Dec
-
07Dec
-
13Dec
-
14Apr